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Abstract: Hepatic encephalopathy (HE) is a common reversible neuropsychiatric syndrome 
associated with chronic and acute liver dysfunction and significant morbidity and mortality. 
Although a clear pathogenesis is yet to be determined, elevated ammonia in the serum and 
central nervous system are the mainstay for pathogenesis and treatment. Management includes 
early diagnosis and prompt treatment of precipitating factors (infection, gastrointestinal 
bleeding, electrolyte disturbances, hepatocellular carcinoma, dehydration, hypotension, and 
use of benzodiazepines, psychoactive drugs, and/or alcohol). Clinical trials have established 
the efficacy of lactulose and lactitol enemas in the treatment of acute hepatic encephalopathy. 
Extensive clinical experience has demonstrated the efficacy of oral lactulose and lactitol with 
the goal of two to three soft bowel movements a day for the treatment of chronic HE. However, 
lactulose and lactitol have significant gastrointestinal side effects. For patients unable to tolerate 
lactulose or lactitol or who still have persistent chronic HE with lactulose or lactitol, neomycin, 
metronidazole and rifaximin are second-line agents. More recent data supports the benefits 
of rifaximin used solely and as an additional agent with fewer side effects than neomycin or 
metronidazole. Newer therapies being investigated in humans with clinical promise include 
nitazoxanide, the molecular adsorbent recirculating system (MARS), L-ornithine phenylacetate, 
sodium benzoate, and/or sodium phenylacetate and Kremezin® (AST-120).
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Introduction
Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated 
with chronic and acute liver dysfunction. It is characterized by cognitive and motor 
deficits of varying severity. Early symptoms include reversal of sleep pattern, apathy, 
hypersomnia, irritability, and personal neglect. In later stages, delirium and coma 
can arise with neurologic signs including hyperreflexia, rigidity, myoclonus, and 
asterixis.1 An important aspect of this syndrome is the diversion of portal blood into 
systemic circulation through portosystemic collateral vessels, without being filtered 
by hepatocytes. HE has also been seen clinically among noncirrhotic patients with 
either spontaneous or surgically created portosystemic shunts.2
Subtle signs of HE are seen in almost 70% of patients with cirrhosis and can have a 
significant impact on a patient’s functional ability. More severe symptoms can be inca-
pacitating in a considerable number of patients with end-stage liver disease and are noticed 
in nearly 30% of patients who experience portosystemic shunt surgery.3 Roughly 30% of 
patients with end-stage liver disease experience significant encephalopathy approaching 
coma that require hospitalization.4 Therefore, HE with cirrhosis is considered a poor Therapeutics and Clinical Risk Management 2009:5 618
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prognostic sign and without liver transplantation the one year 
survival rate is 42% after the first episode of overt HE and 
the three-year survival rate is 23%.5
There are two classification systems that are frequently 
used to assess hepatic encephalopathy. The World Congress 
of Gastroenterology has categorized HE based on underlying 
hepatic abnormalities and for patients with cirrhosis it can 
be further subdivided by the duration and characteristics of 
neurologic dysfunction. The three types of HE are A, B, 
and C which are associated with Acute liver failure, por-
tal systemic Bypass without intrinsic liver disease, and 
Cirrhosis, respectively.6–8
Encephalopathy has been further subdivided, based on 
duration and characteristics of neurologic dysfunction, into 
episodic, persistent, and minimal subtypes. Episodic HE occurs 
over a short time span and fluctuates in severity. Persistent HE 
is a chronic clinical condition of cognitive deficits that affects 
social and occupational functioning. Minimal HE is associ-
ated by subtle cognitive impairments of attention, response 
inhibition and executive function. The other frequently used 
classification system is the West Haven criteria. The West 
Haven criteria is a routinely used grading system to assess the 
severity of symptoms in patients with overt HE (Table 1).9 The 
majority of these symptoms are manageable with treatment, 
and reversible with liver transplantation.
Pathophysiology
Decades of clinical experience and research has failed to 
establish a clear pathogenesis of HE. The pathophysiology 
is not a single clinical entity, rather a complicated interplay 
of many factors and the abnormalities involving ammonia 
metabolism is the most frequently implicated factor. The 
normal gut flora produces a urease that enzymatically cleaves 
ammonia (NH3) from protein in the small bowel and colonic 
lumen. Ammonia is then absorbed into the portal circulation. 
It reaches the systemic circulation via portosystemic shunting 
and the inability of the liver to metabolize ammonia.10 
Excessive plasma ammonia can accumulate in the central 
nervous system (CNS) causing significant alteration in 
neurotransmission. Excessive levels of ammonia have can be 
seen in the basal ganglia and cerebellum of cirrhotic patients 
with HE.11,12 It is believed that this contributes to the increase 
prevalence of motor dysfunction and the extra pyramidal 
symptoms exhibited with HE.
Other clinical observations possibly involved in the 
pathogenesis of HE are decreased serum levels of branched-
chain amino acids and increased brain levels of aromatic 
amino acids.13 The principal neuro-inhibitory neurotransmitter 
gamma-aminobutyric acid (GABA) is also increased in the 
cerebral spinal fluid (CSF) of patients with encephalopathy. 
Other toxins identified in the CNS include increased levels 
of endogenous benzodiazepine-like compounds, manga-
nese, oxygen free radicals, circulation opioid peptides, 
nitric oxide, inflammatory cytokines, reduction in sero-
toninergic neurotransmitters, and depletion of endogenous 
antioxidants.14–17 Thus, the pathophysiology of HE is a 
result of several complicated factors rather than a single 
mechanism.
Diagnosis
The diagnosis of minimal HE can only be made by 
administering psychometric tests, including the portosys-
temic HE score (PHES). The testing of patients is time 
consuming and requires psychological expertise for admin-
istering and interpreting the results. The critical flicker 
frequency is a highly objective and sensitive measure of 
minimal hepatic encephalopathy, but requires purchase 
of equipment and a closed room without distractions.18–20 
Magnetic resonance spectroscopy (MRS) is currently being 
studied, but due to variability among initial studies and costs 
it not used clinically.21 Overt HE is a diagnosis of exclusion. 
Similar neuropsychiatric symptoms are seen in a variety of 
metabolic disorders, toxic ingestions, infectious processes 
or intracranial processes. In patients with cirrhosis and 
portosystemic shunting, a known precipitating factor and a 
typical clinical presentation is usually sufficient to make a 
diagnosis. Lab testing is necessary to exclude treatable causes 
Table 1 west Haven criteria for altered mental status in hepatic 
encephalopathy
Minimal hepatic encephalopathy
Minimal changes in memory and lack of detectable changes in personality 
or behavior. No asterixis.
Grade 1
Trivial lack of awareness, shortened attention span, sleep disturbance, 
altered mood, and slowing the ability to perform mental tasks.   Asterixis 
can be detected.
Grade 2
Lethargy or apathy, disorientation to time, amnesia of recent events, 
impaired simple computations, inappropriate behavior, slurred speech. 
Asterixis is present.
Grade 3
Somnolence, confusion, disorientation to place, bizarre behavior, clonus, 
nystagmus, and positive Babinski sign.   Asterixis usually absent.
Grade 4
Coma with or without response to painful stimuli.Therapeutics and Clinical Risk Management 2009:5 619
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such as hypoxia, azotemia, hyponatremia, hypoglycemia, and 
other psychoactive drugs. Arterial or venous ammonia levels 
may be helpful in securing the diagnosis and correlate with 
the severity of the disease.22 A physical exam is important 
to identify other potential causes. Further work up may be 
warranted to exclude other potential causes in difficult to 
diagnose patients, including additional laboratory studies, 
electroencephalogram, lumbar puncture, and/or imaging of 
the head.
Treatment
The protocols used to treat patients with HE were derived 
in the 1970s, but many of the studies had flaws in their 
design.23,24 Most of the studies lacked standard definitions 
and grading scales of hepatic encephalopathy, included 
small sample sizes, and rarely used a placebo control group. 
Despite these limitations the studies findings that removal 
of ammonia from the body is critical to the treatment of HE 
is still widely adhered to by clinicians. Hyperammonemia is 
detected in over 80% of patients with HE. Therefore, treat-
ment is aimed at:
•  Excluding nonhepatic causes of altered mental function.
•  Treating precipitating factors.
•  Initiating treatments based on the ammonia hypothesis.
•  Managing severe encephalopathy in the intensive care 
unit with full medical support.
Treatment of precipitating causes
The most important aspect of HE management is prompt 
recognition and treatment of precipitating factors rather than 
assuming a deterioration of hepatocellular function. Fessel 
and colleagues demonstrated that HE is caused by reversible 
factors in over 80% of patients.25 These common reversible 
factors include constipation, infection, hypokalemia, gastro-
intestinal bleeding, increased protein intake, sedatives, and 
tranquilizers. Thus, identifying and correcting the revers-
ible precipitating factors can be beneficial in treating most 
episodes of HE.
Treatment based 
on the ammonia hypothesis
Dietary issues
There is no substantial evidence to support protein restriction 
among cirrhotic patients. Therefore a diet with approxi-
mately 1 to 1.5 g of  dietary protein per kilogram of  body 
weight per day can be administrated safely to a patient with 
hepatic encephalopathy. In a randomized study, Cordoba and 
colleagues demonstrated that a protein-restricted diet does 
not improve HE in cirrhotic patients.26 The source of proteins 
may be important to controlling HE. Bianchi presented in 
a randomized crossover trial that vegetable proteins were 
superior to animal-derived proteins.27 In addition, a high fiber 
diet may be beneficial by increasing the transit rate of food 
through the intestines and lowering the pH of the colonic 
lumen as a result of its fermentation by colonic bacteria.28 
Branched-chain amino acids appear to be more tolerable 
with a positive nitrogen balance however supplementation 
with branched-chain amino acids have failed to show any 
improvement in morbidity or mortality among patients with 
HE.29,30 As a general rule, patients who develop deteriorating 
HE from an animal-derived protein diet warrant substituting 
a well-balanced diet with vegetable proteins and a high 
fiber diet.
Pharmacologic approach
Nonabsorbable disaccharides in the reduction 
of intestinal ammonia production and absorption
Lactulose  (beta-galactosidofructose)  and  lactitol 
(beta-galactosidosorbitol) are nonabsorbable disaccharides 
that are currently used as first line agents for the treatment 
of HE. Lactitol is not available in the United States. The exact 
mode of action by lactulose is thought to be the conversion 
to lactic acid and acetic acid resulting in acidification of the 
gut lumen. This favors conversion of ammonia (NH3) to 
ammonium (NH4
+), which is relatively membrane imper-
meable; therefore, less ammonia is absorbed by the colon. 
Gut acidification inhibits ammoniagenic coliform bacteria, 
leading to increased levels of nonammoniagenic lactobacilli. 
Nonabsorbable disaccharides also work as a cathartic, clear-
ing the gut of ammonia before it can be absorbed. Als-Nielsen 
and colleagues were able to demonstrate, in a systemic 
review, that lactulose and lactitol are more effective than a 
placebo in treating HE.31 However, they failed to show any 
benefit in survival rates. In a controlled trial of 61 patients, 
Prasad and colleagues showed lactulose improves cognitive 
function and health related quality of life among patients 
with cirrhosis who have minimal HE.32 In a double-blinded 
randomized trial, Morgan and colleagues showed lactitol was 
more tolerable and produced fewer side effects than lactulose.33 
In a double-blinded randomized study, Uribe and colleagues 
showed lactulose and lactitol enemas were more effective 
than tap water in 20 patients. This suggests that colonic acidi-
fication is more important than bowel cleansing.34
Treatment of acute episodes of HE include nonabsorbable 
disaccharides administered orally or through a nasogastric Therapeutics and Clinical Risk Management 2009:5 620
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tube at an initial dose of 45 ml, followed by a repeated dose 
every hour until the patient has a bowel movement. For 
patients at risk of aspiration, lactulose (or lactitol) can be 
administered as an enema (300 ml in 700 ml of water, retained 
for one hour in the Trendelenburg position) every two hours 
as needed until mental function improves. After clinical 
improvement of HE and once the risk of aspiration becomes 
minimal, lactulose (or lactitol) can be administered orally 
and titrated to achieve two to three soft bowel movements 
daily (the usual oral dosage is 15–45 ml every 8–12 hours). 
For patients with chronic encephalopathy and for prevention 
of episodic HE the daily dosage of nonabsorbable disac-
charides should be titrated to maintain 2–4 soft bowel 
movements daily. The main side effects of nonabsorbable 
disaccharides include an excessively sweet taste, flatulence, 
abdominal cramping, and electrolyte imbalance, particularly 
hypernatremia, which can deteriorate the patient’s mental 
status. For patients who can not tolerate the sweet taste of 
lactulose a powder packet is available.
Antibiotics in the reduction of intestinal 
ammonia production
Certain oral antibiotics can reduce urease-producing 
bacteria in the intestines, resulting in a decrease of ammonia 
production and absorption through the gastrointestinal 
tract. Antibiotics are used generally in patients who do not 
tolerate nonabsorbable disaccharides or in patients who are 
symptomatic on nonabsorbable disaccharides and require a 
second agent.
Rifaximin
Rifaximin is an oral nonsystemic antibiotic with less 
than 0.4% absorption. It was granted an orphan drug 
designation by the US Food and Drug Administration (FDA) 
for use in hepatic encephalopathy. A phase III multicenter, 
randomized, double-blinded, placebo-controlled trial involv-
ing 299 patients using rifaximin 550 mg orally twice a 
day or placebo for six months was recently completed and 
showed that patients who received rifaximin for six months 
had highly statistically significant protection against clinical 
HE breakthrough episodes (58% risk reduction, p  0.0001) 
compared to placebo.35 Rifaximin is currently being reviewed 
by the FDA for approval. In a randomized double-blind, 
double dummy and controlled trial, Mas and colleagues 
showed rifaximin is as effective as lactitol in patients 
with moderate to severe HE.36 A review by Lawrence and 
colleagues concluded that rifaximin is equally effective and 
in some studies superior to nonabsorbable disaccharides 
and other antimicrobials in relieving the signs and symptoms 
observed in cirrhotic patients with mild-to-moderately severe 
HE.37 Additional well-designed studies will be needed to 
fully delineate the efficacy of rifaximin with or without 
nonabsorbable disaccharides in patients with HE.
Neomycin
Neomycin is FDA-approved for the treatment of acute HE, 
but not chronic HE. Neomycin has been used clinically for 
many years to treat hepatic encephalopathy, yet there are no 
controlled studies finding it to be as effective as lactulose. 
Conn and colleagues demonstrated that neomycin is as effec-
tive as lactulose in 33 patients.38 However, in a more recent 
randomized study by Strauss, neomycin was shown to be no 
better than a placebo in 39 patients with HE.39 In acute enceph-
alopathy, neomycin can be administered orally at a dose of 
1000 mg orally every six hours for up to six days. For chronic 
encephalopathy the dosage routinely used is 1–2 g daily. 
Although neomycin is poorly absorbed, its chronic admin-
istration may result in nephrotoxicity and ototoxicity.40,41 
Patients who are maintained on chronic neomycin must have 
periodic evaluation for potential side effects.
Metronidazole
Metronidazole is not an FDA-approved antibiotic for 
the treatment of HE. In a report of 11 mild to moderate 
HE patients and seven chronically affected HE cirrhotic 
patients treated with metronidazole for one week, Morgan 
and colleagues showed metronidazole to be as effective as 
neomycin.42 The recommended oral dose of metronidazole 
for chronic use is 250 mg bid. Prolonged administration of 
metronidazole can be associated with gastrointestinal distur-
bance and neurotoxicity.
Nitazoxanide
Nitazoxanide is an oral agent indicated for the treatment 
of infectious diarrhea caused by Crytpsporidium parvum 
and Giardia lamblia. Basu and colleagues presented a 
pilot prospective study at the 2008 American Association 
for the Study of Liver Diseases meeting showing clinical 
improvement in HE among cirrhotic patients who received 
nitazoxanide and lactulose.43 Results such as these are 
encouraging larger studies.
Combination of disaccharides and antibiotics
A combination of disaccharides and antibiotics is generally 
used in difficult to treat patients with HE, but clinical data is 
limited. In a retrospective chart review of 213 cases, Mantry 
and colleagues showed that the number of hospitalizations Therapeutics and Clinical Risk Management 2009:5 621
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and the duration of hospital stays were shortened for patients 
receiving combination therapy compared with those receiving 
lactulose monotherapy. Additional studies to further investi-
gate the potential therapeutic benefit of combination therapy 
will be needed.44,45
The phase III multicenter, randomized, double-blinded, 
placebo controlled trial involving 299 patients using refaximin 
versus placebo mentioned earlier allowed patients to continue 
on lactulose. Over 90% of the study participants received 
lactulose. A sub-analysis of these patients also showed 
clinical prevention against HE compared to placebo.35
Drugs and devices aimed at elimination  
of ammonia from plasma
Ornithine-aspartate
Ornithine-aspartate is a stable salt of two amino acids 
used for the treatment of HE, which is not yet available in 
the United States. Ornithine-aspartate is both involved in 
hepatic and muscle metabolism of ammonia, through urea 
cycle and glutamine synthesis. Ornithine-aspartate is avail-
able in both enteral and parenteral forms and has been used 
to enhance metabolic conversion of ammonia through both 
pathways. In a trial of 126 patients with cirrhosis and mild 
chronic hepatic encephalopathy, a daily dose of ornithine-
aspartate at 20 g administered intravenously of over a period 
of one week resulted in lower serum ammonia levels and 
reduced HE versus placebo.46 In a smaller trial, ornithine-
aspartate administered at a dose of 18 g daily for a period 
of two weeks resulted in a significant decrease in serum 
fasting and postprandial ammonia levels as well as signifi-
cant improvement in mental status and cognitive function 
in patients with chronic overt and minimal encephalopathy 
when compared to a placebo.47 Except for mild gastroin-
testinal disturbance, no major side effects of this therapy 
have been reported.
L-ornithine phenylacetate
L-ornithine phenylacetate has also been considered in 
the treatment of HE. L-ornithine would participate in the 
clearance of ammonia in muscles and the liver through 
glutamine synthesis and the phenylacetate would conjugate 
with glutamine (which contain nitrogen from ammonia) 
to form phenylacetylglutamine. Phenylacetylglutamine is 
excreted by the kidneys by glomerular filtration and tubular 
secretion. The theoretical benefit of this combination over 
the ornithine-aspartate combination is the ability to excrete 
phenylacetylglutamine into the urine.48 Human clinical trials 
are needed to confirm this theory.
Sodium benzoate and/or sodium phenylacetate
Sodium benzoate and/or sodium phenylacetate are shown 
to enhance tissue metabolism of ammonia. Benzoate conju-
gates with glycine (which contain nitrogen from ammonia) 
to form hippuric acid and phenylacetate conjugates with 
glutamine (which contain nitrogen from ammonia) to form 
phenylacetylglutamine. Both hippuric acid and phenylacetyl-
glutamine are excreted by the kidneys by glomerular filtration 
and tubular secretion. The combination of sodium benzoate 
with sodium phenylacetate orally was used in a small study, 
which suggested it may be beneficial in the treatment of HE.49 
An oral dose of 5 g bid of sodium benzoate was as effective 
as lactulose in reducing serum ammonia levels and improv-
ing cognitive function.50 Routine use of the oral forms of 
both or either agent alone has been limited by concern of the 
sodium load and increased frequency of adverse gastrointes-
tinal symptoms particularly nausea. Ammonul (10% sodium 
benzoate and 10% sodium phenylacetate) is FDA-approved 
intravenously for the treatment of hyperammonemia associ-
ated with urea cycle disorders. This agent may also have a 
role in the treatment of HE, but clinical trials are needed.51
L-Carnitine
L-Carnitine is shown to stimulate the urea cycle and a 
delayed onset of HE in hyperammonemic mice. Therrien 
demonstrated that L-carnitine protects against ammonia 
neurotoxicity among patients after portacaval-shunt surgery, 
however, well designed studies are pending.52
Molecular adsorbent recirculating system (MARS)
Molecular adsorbent recirculating system (MARS) is a blood 
detoxification system based on albumin dialysis. The system 
removes both protein-bound and water-soluble toxins, which 
makes it useful for patients with liver failure. The FDA has 
approved MARS as a toxin removal device in cases of drug 
overdose and poisoning, however it is not approved for HE. 
The principal mechanism in MARS therapy is hemodiadsorp-
tion, which combines hemodialysis with adsorption using 
albumin. A prospective, controlled, randomized multicenter 
trial in patients with HE (grade 3 or 4) was randomized to 
standard medical therapy or MARS dialysis with standard 
medical therapy. The MARS dialysis-treated group had a 
more significant and rapid improvement in their mental status 
compared to standard medical therapy.53
Drug effects on neurotransmission
Branched-chain amino acids
Branched-chain amino acids are decreased and aromatic 
amino acid are increased in patients with cirrhosis Therapeutics and Clinical Risk Management 2009:5 622
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and HE. This imbalance may competitively inhibit normal 
neurotransmitters such as dopamine and norepinephrine.54,55 
Attempts to correct this imbalance with the administration of 
branched-chain amino acids intravenously and orally have 
been performed for many decades. In a meta-analysis of 
five studies using intravenous branched-chain amino acids 
infusions to treat HE, a significant improvement of HE was 
observed overall, but in two of the studies there was an 
increase in mortality.56 Large multicenter studies are needed 
before branched-chain amino acids can be used clinically.
Flumazenil
Flumazenil, a short-acting benzodiazepine receptor 
antagonist, has been used as a treatment for patients with HE. 
There is evidence of an increase in benzodiazepine receptor 
activation among cirrhotic patients with HE. In a systematic 
review, Als-Nielsen and colleagues included 12 controlled 
trials with a total of 765 patients and found flumazenil to be 
associated with a significant improvement in HE. However, 
it failed to show any long-term benefits or improvement in 
survival.57 Flumazenil is not routinely used as therapy for 
HE because of significant side effects including seizures, 
nausea, vomiting, dizziness, and agitation.
Bromocriptine
Bromocriptine, which stimulate dopamine receptors, is 
approved for Parkinson’s disease. A reduction in dopaminergic 
neurotransmission has been proposed as one of the underly-
ing mechanisms for HE. Improvement of extrapyramidal 
symptoms has been reported when bromocriptine was added 
to more conventional therapies.58 Bromocriptine at 30 mg 
orally twice daily can be considered in patients who are refrac-
tory to other therapies with extrapyramidal symptoms.6
Zinc
Zinc deficiency is common among cirrhotic patients, espe-
cially with alcohol-induced liver injury. Zinc supplementa-
tion has been shown to decrease serum ammonia levels and 
altering neurotransmitters like gamma-aminobutyric acid 
and norepinephrine in the brain.59 Only small studies have 
been performed using zinc supplementation with equivocal 
results.60,61 Zinc is an oral agent that is available over-the-
counter and has a role for patients with zinc deficiency. Zinc 
is available in several forms including zinc gluconate, zinc 
sulfate, and zinc acetate. The recommended daily allowance 
of elemental zinc is 11 mg in adult males and 8 mg in adult 
females. The elemental zinc content appears in the supple-
mental facts panel on the supplement container. Zinc toxicity 
can occur in both acute and chronic forms. Acute adverse 
effects of high zinc intake include nausea, vomiting, loss of 
appetite, abdominal cramps, diarrhea, and headaches.
Surgical treatments
Obliteration of large spontaneous portosystemic anastomoses, 
surgical shunts, or transjugular intrahepatic portosystemic 
shunt (TIPS) can be a therapeutic option among chronic 
HE patients. However, the risk of bleeding and hepatic 
decompensation should be taken into account when those 
procedures are performed. Splenic artery embolization or 
total colectomy are other possibilities that have been used 
in highly selected patients with chronic HE who are resilient 
to medical therapy.8,11
Liver transplantation is the ultimate curative treatment 
available for liver disease and HE. Appropriate candidates 
should be referred to a liver transplant center after the first 
episode of overt encephalopathy due to its poor prognostic 
sign.4 The model for end-stage liver disease (MELD) system 
used for organ allocation in the United States includes objec-
tive data (serum creatinine, total bilirubin, and international 
normalized ratio of prothrombin time) and does not include 
any subjective data (including HE). Objective data is used 
since it verifiable, but excluding subjective data does a 
disservice to patients with HE and low MELD scores.
Miscellaneous treatments
AST-120
AST-120 (Kremezin®; Kureha Corp., Tokyo, Japan) is an 
oral adsorbent used in Japan for delaying the initiation of 
dialysis for patients with chronic kidney disease.62 AST-120 
adsorbs to toxins and mediators of inflammation from the 
gastrointestinal tract, including ammonia, bile acids, hista-
mine, serotonin, tyramine, tryptamine and octopamine. It is 
currently undergoing a phase 2, multicenter, randomized, 
double-blinded, placebo-controlled, dose-ranging trial to 
evaluate the efficacy, safety, and tolerability for eight weeks 
in patients with mild HE.63
Probiotics
Probiotics is a medical therapy that attempts to alter colonic 
flora for a clinical benefit. Probiotics have been used to treat 
HE by decreasing urease-producing bacteria and promoting 
growth of nonurease-producing bacteria. Loguerico and 
colleagues reported in a pilot study that Enterococcus faecium 
was as effective as lactulose in reducing ammonia levels 
and improving mental status among chronic HE patients.64 
In another pilot study by Liu, probiotics improved cognitive Therapeutics and Clinical Risk Management 2009:5 623
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functioning in 50% of patients with minimal HE.65 One 
should note that probiotics are not largely used clinically 
due to the fear of introducing live bacteria into patients who 
are in an immunosuppressed state.
Acarbose
Acarbose is an FDA-approved medication for the treatment 
of type 2 diabetes mellitus. It inhibits alpha-glucosidase 
activity in the intestine and delays digestion of ingested 
carbohydrates. For patients with HE, acarbose can decrease 
colonic proteolytic flora and the degradation of dietary 
nitrogenous substances. Gentile and colleagues demonstrated 
in a randomized, controlled and crossover trial, significant 
reduction in blood ammonia coupled with clinical improve-
ment of HE in 107 cirrhotic patients treated with acarbose 
150–300 mg/day compared to a placebo.66 This drug is not 
routinely used for the management of HE because the product 
information sheet states that acarbose is contraindicated in 
patients with cirrhosis.
Manganese
Manganese deposition in many cirrhotic brains (globus 
pallidus) has been detected by magnetic resonance imag-
ing (MRI), which disappears after liver transplantation and 
HE.67 Although there are no significant correlations between 
plasma manganese levels and HE, the similarity in clinical 
symptoms between HE and manganese toxicity makes it an 
interesting area for further studies to evaluate the effects of 
manganese-chelating agents on HE treatment.68
N-methyl-D-aspartate
N-methyl-D-aspartate (NMDA) receptors can interact with 
glutamate in the brain to activate many enzymes, includ-
ing nitric oxide synthetase. Nitric oxide can activate other 
pathways important to cerebral processes such as circadian 
rhythms, memory and learning. Hyperammonemia enhances 
glutamatergic activity and overstimulation of NMDA recep-
tors in the brain. Hyperammonemia induced rats develop 
neurologic symptoms similar to HE, but many of these 
symptoms resolve with the administration of NMDA receptor 
antagonists.69 Human studies are still pending.
Conclusions
The treatment of acute or persistent HE has changed very 
little during the past forty years. However, with newer 
agents under investigation, the available treatment options 
will increase over the next five years. Until then treatment 
options are limited to correcting or removing precipitating 
causes, dietary changes and pharmacologic approaches 
that are focused on the use of nonabsorbable disaccharides. 
Additional pharmacological agents available include certain 
antibiotics, drugs to eliminate ammonia from the plasma, and 
a few other drugs with special indications.
A complete list of precipitating factors associated 
with acute episodes of HE or persistent HE are identified 
in Table 2. The most common causes include infection, 
gastrointestinal bleeding, electrolyte abnormalities, dehydra-
tion, use of alcohol or benzodiazepines, and constipation. 
A complete history, physical exam, and laboratory studies 
should identify most of these causes.
Dietary changes can prevent episodes of acute HE and 
persistent HE. A diet focused on vegetable-based protein 
source and high fiber can be associated with developing 
less HE.
The first line agent used to prevent acute or persistent HE 
are the nonabsorbable disaccharides (lactulose or lactitol). 
Clinical trials have established the efficacy of the nonabsorb-
able disaccharides in enema form to treat acute episodes 
Table 2 Common precipitants of hepatic encephalopathy and the 
underlying mechanisms
1.  increased nitrogen load
  a.  excess dietary protein
  b.  Constipation
  c.  Gastrointestinal bleeding
  d.  Blood transfusions
  e.    Azotemia
  f.   infection
  g.  Hypokalemia
2.  Decrease toxins clearance
  a.  Dehydration
      i.      Fluid restriction
    ii.    excessive diuresis
    iii.    Abdominal paracentesis
    iv.  Diarrhea due to laxatives
  b.  Hypotension
      i.     Bleeding
    ii.    Systemic vasodilatation
  c.    Anemia
  d.  Porto systemic shunts (iatrogenic and spontaneous)
3.    Altered neurotransmission
  a.  Benzodiazepines
  b.  Psychoactive drugs
4.  Hepatocellular damage
  a.  Continued alcohol abuse
  b.  Development of hepatocellular carcinomaTherapeutics and Clinical Risk Management 2009:5 624
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of HE. Extensive clinical experience has demonstrated the 
efficacy of oral nonabsorbable disaccharides. Unfortunately, 
not all patients are able to tolerate these agents. For patients 
who can not tolerate the sweet taste of lactulose a powder 
packet is available. For patients who develop gastrointesti-
nal bloating or debilitating diarrhea a second line agent is 
considered.
The second line agents include oral antibiotics (neomycin, 
metronidazole, and rifaximin) that can reduce urease-
producing bacteria in the intestines, resulting in a decrease of 
ammonia production and absorption through the gastrointes-
tinal tract. Both neomycin and metronidazole have been used 
for many years to treat HE and are inexpensive. However, 
the potential side effects of neomycin (ototoxicity and renal 
insufficiency) and metronidazole (peripheral neuropathy) 
limit their use. Rifaximin has minimal side effects and is 
effective, but the cost of US$5 for a 200 mg tablet limits its 
clinical use.70
The third line agents available for patients who can not 
tolerate the above agents or still have persistent or episodic 
HE on the above agents are sodium benzoate, zinc, or 
bromocriptine. In addition, patients with unique situations 
may also benefit from an agent in this class. Sodium benzoate 
is inexpensive, but is associated with a large sodium load 
and gastrointestinal side-effects. Most patients can not 
tolerate the 5 g twice a day and will need to start at a lower 
dose and slowly titrate up. The prescription must be filled 
by a compounding pharmacy and is not always paid for by 
insurance companies. Zinc is an oral agent that is available 
over-the-counter and has a role for patients with zinc 
deficiency. Bromocriptine has been used by the authors with 
benefit in the patient with extrapyramidal symptoms.
Table 3 Treatment summary
First line agents: (Level ii-1–ii-3)
Lactulose or Lactitol
Acute He – enemas: 300 ml in 1000 ml every two hours until clinical improvement.
Acute He – oral: 45 ml each hour until bowel movement and clinical improvement.
Chronic He – oral: 15–45 ml tid or bid continuous until two to three bowel movements per day.
Second line agents: (Level i–iii)
Rifaximin (Level i)
Chronic He – oral: 400–550 mg po bid
Neomycin (Level iii)
Acute He – oral: 1 g every six hours for up to six days
Chronic He – oral: 1–2 g/day
Metronidazole (Level iii)
Chronic He – oral: 250 mg bid
Third line agents: (Level ii-3–iii)
Sodium benzoate (Level ii-3)
Chronic He – oral: titrate up to clinical improvement or a maximum dose of 5 g bid
Elemental zinc from zinc gluconate, zinc sulfate, and zinc acetate (Level ii-3)
Chronic He – oral: 11 mg in adult males and 8 mg in adult females every day
Bromocriptine (Level iii)
Chronic He – oral: 30 mg bid
Fourth line agents: (Level ii-3)
Chronic He – surgical obliteration of large spontaneous portosystemic anatomoses, splenic artery embolization, or total colectomy.
The US Preventive Services Task Force evidence ranking71
  •  Level i: evidence obtained from at least one properly designed randomized controlled trial.
  •  Level ii-1: evidence obtained from well-designed controlled trials without randomization.
  •  Level ii-2: evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.
  •    Level ii-3: evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be 
regarded as this type of evidence.
  •  Level iii: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.Therapeutics and Clinical Risk Management 2009:5 625
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Patients who are still symptomatic with HE despite all 
of the above may benefit from surgical options including 
obliteration of large spontaneous portosystemic anatomoses, 
splenic artery embolization or total colectomy. HE in 
cirrhotic patients is associated with a survival lower than 50% 
at one year. Therefore liver transplant should be considered in 
those patients as the ultimate cure, unfortunately the MELD 
system does not prioritize the allocation of organs to those 
recipients with HE (Table 3).
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